Publisher
Japanese Society of Clinical Pharmacology and Therapeutics
Subject
Pharmacology (medical),Pharmacology
Reference13 articles.
1. 1) Keystone EC. Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol. 2003; 15(3): 253-8.
2. 2) Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993; 36(12): 1681-90.
3. 3) Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol. 1999; 163(3): 1521-8.
4. 4) Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343(22): 1594-602.
5. 5) Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004; 363(9410): 675-81.